Dab389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma

American Journal of Hematology

Volumn 58, Issue 1, 1998, Pages 87-90

  Duvic, Madeleine ^a   Cather, Jennifer ^a   Maize, John ^b   Frankel, Arthur E ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NONE   (United States)

Author keywords

Cutaneous T cell lymphoma (CTCL); DAB389IL2; IL2R; Topical therapies

Indexed keywords

CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; PREDNISOLONE; VINCRISTINE SULFATE; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; EDEMA; FEMALE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; MALE; MYALGIA; PRIORITY JOURNAL; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME; ULCER; WEIGHT GAIN; WHEEZING; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0031596951     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199805)58:1<87::AID-AJH18>3.0.CO;2-2     Document Type: Article

References (11)

1. Wood GS, Weiss LM, Warnke RA, Sklar J: The immunopathology of cutaneous lymphomas: Immunophenotypic and immunogenetic characteristics. Semin Dermatol 5:334-345, 1986.
2. Holloway KB: Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 27:367-378, 1992,.
3. Olsen EA, Rosen ST, Vollmer RT, et al: Interferon alpha-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 20: 395-403, 1989.
4. Takeshita T, Asao H, Ohtani K, Ishii N, et al: Cloning of the γ chain of the human IL2 receptor. Science 257:357-382, 1992.
5. Foss, F, Borkowski T, Gilliom M, Stetler-Stevenson M, et al: Chimeric fusion protein toxin DAB486IL2 in advanced mycosis fungoides and the Sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 84:1765-1774, 1994.
6. 486-IL2: Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 265:11885-11889, 1990.
7. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G: Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 33(Suppl 1):S34-S36, 1997.
8. Liskay AM, Mion LC, Davis BR: Comparison of two devices for wound measurement. Dermatol Nurs 5:437-441, 434, 1993.
9. Stone MJ, Sausville EA, Fay JW, Headlee D, et al: A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88:1188-1197, 1996.
10. 389IL2 in cultured hematopoietic cells. Cancer Res 56:2590-2595, 1996.
11. Thompson J, Hu H, Scharff J, Neville DM: An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 270:28037-28041, 1995.